| ORIGINAL ARTICLE |
|
| Year : 2022 | Volume
: 6
| Issue : 2 | Page : 97-102 |
|
|
Immunohistochemical demonstration of interleukin-17 positivity in skin biopsy specimens of patients with chronic plaque psoriasis and its correlation with severity of psoriasis and associated metabolic syndrome and cardiovascular changes
Madivalara Yallappa Suparna1, Praveen Kumar Shanmugam Reddy1, Tharayil Kunneth Sumathy1, Vijaya V Mysorekar2
1 Department of Dermatology, M.S. Ramaiah Medical College, Bengaluru, Karnataka, India
2 Department of Pathology, M.S. Ramaiah Medical College, Bengaluru, Karnataka, India
Correspondence Address:
Praveen Kumar Shanmugam Reddy
T2, 3rd Main, 2nd Cross, 1st Block, Koramangala, Bengaluru - 560 034, Karnataka
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/cdr.cdr_17_22
|
|
|
Background: Psoriasis is a chronic inflammatory disease which can be associated with metabolic syndrome and cardiovascular abnormalities. Objectives: The aim and objective of the study are to demonstrate interleukin-17 (IL-7) positivity in histopathological sections of psoriatic plaques and to correlate with metabolic syndrome and cardiovascular changes. Materials and Methods: Forty-seven patients with chronic plaque psoriasis with body surface area >10% and psoriasis area and severity index (PASI) score >12, in whom skin biopsy showed munro's microabscesses, were evaluated for IL-17 positivity (intensity and proportion) with associated metabolic syndrome according to the National Cholesterol Education Program adult treatment panel III criteria and cardiovascular comorbidities. A co-relation with PASI score was made. IL-17 intensity and proportion were graded with a score ranging from 0 to 3. IBM SPSS version 16.0 was used for statistical analysis and independent t-test and Chi-square test were used for proportion. Results: The mean age of patients was 43 years. A total of 15 (31.9%) female and 32 (68.1%) male patients were enrolled. The mean PASI score was 21.6. Metabolic syndrome was seen in 31 (65.96%) patients. There was statistically significant association with raised diastolic blood pressure in patients with metabolic syndrome (P = 0.042). The total number of patients with IL-17 positivity with metabolic syndrome was 21 (63.6%). Of these, 9 (42.9%) cases showed IL-17 positivity in the munro's microabscess, 14 (66.7%) cases in the rest of the epidermis, and 18 (85.7%) cases in the dermis. Conclusion: In our study, there was no significant difference in IL-7 positivity between patients with or without metabolic syndrome. Further studies need to be done with large sample size to confirm the significance.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
